FDA Confirms Decision to Withdraw Melphalan Flufenamide Approval in Multiple Myeloma

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

Related Keywords

New York ,United States ,Joshua Richter ,Fredrik Schjesvold ,Peter Marks ,Oncopeptide Pepaxti ,Tisch Cancer Institute ,European Commission ,Chelsea Medical Center At Mount Sinai ,Division Of Hematology ,Drug Administration ,Oncologic Drugs Advisory Committee ,European Union ,Biologics Evaluation ,Federal Register ,Orange Book ,Medical Oncology ,Multiple Myeloma ,Blavatnik Family Chelsea Medical Center ,Mount Sinai ,Accessed February ,Pepaxto ,Melphalan Flufenamide ,Melflufen ,Myeloma ,Ocean Trial ,Fdas Center For Biologics Evaluation And Research ,Fda ,